Recombinant Human TNFRSF18 Protein, Fc-tagged, Alexa Fluor 555 conjugated

• Cat.No.: TNFRSF18-554HAF555
• Product Overview: Alexa Fluor 555 conjugated recombinant human TNFRSF18 (Q9Y5U5-1) (Met1-Glu161), fused with the Fc region of human IgG1 at the C-terminus, was produced in Human Cells.

Specification

• Source: HEK293
• Species: Human
• Tag: Fc
• Form: Lyophilized
• Molecular Mass: The recombinant human TNFRSF18/Fc is a disulfide-linked homodimer. The reduced monomer comprises 377 amino acids and has a predicted molecular mass of 41.5 kDa. The apparent molecular mass of the protein is approximately 96 and 45 kDa in SDS-PAGE under re
• Protein length: 377
• N-terminal Sequence Analysis: Gln 26
• Endotoxin: < 1.0 EU/ μg of the protein as determined by the LAL method.
• Purity: > 90 % as determined by SDS-PAGE
• Characteristic: Disulfide-linked homodimer
  Labeled with Alexa Fluor 555 via amines
  With an excitation and emission maximum of 555/565 nm, Alexa Fluor 555 can be efficiently excited using a 543 nm He-Ne laser line and detected under standard TRITC/Cy3 filters.
• Stability: Samples are stable for up to 12 months from date of receipt at -70 centigrade.
• Storage: Store it under sterile conditions at -20 to -70 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Storage Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5%-8% trehalose and mannitol are added as protectants before lyophilization.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4 centigrade before opening to recover the entire contents.

Gene Information

• Gene Name: TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens ]
• Official Symbol: TNFRSF18
• Gene ID: 8784
• mRNA Refseq: NM_004195
• Protein Refseq: NP_004186
• MIM: 603905
• UniProt ID: Q9Y5U5

Reviews

12/20/2021

This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

03/05/2020

Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

10/01/2017

The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

Q&As

What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment?

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment?

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies?

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes?

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies?

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.